Tag: LINNC Paris 2026
Confidence in surface modification bolstered by one-year COATING trial results
This advertorial is sponsored by WallabyPhenox.
New clinical data from the COATING randomised controlled trial (RCT)—presented for the first time at the 2026 LINNC Paris...
“The low-hanging fruit is gone”: larger trials and more proactive treatment...
With mechanical thrombectomy now long-established in ischaemic stroke care, its continued expansion as well as further improvements in associated outcomes moving forward will be...
New ‘small-vessel occlusion’ definition may hold key to reproducible outcomes in...
Owing to the “confusion” created by recent randomised controlled trials (RCTs) evaluating mechanical thrombectomy in more distally located stroke-causing occlusions, the neurointerventional community should...
Jacques Moret bows out after more than 25 years as LINNC’s...
At this year’s LINNC Paris (1–3 June, Paris, France), neurointerventional pioneer Jacques Moret (Bicêtre University Hospital, Paris, France) stepped down from his role as...
Cathpax rolls out Nova-X radiation protection system across multiple European sites
Cathpax, a spinoff of nuclear radiation protection group Lemer Pax, announced today the commercial launch of its Nova-X radiation protection system in Europe and...
